{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:57:58Z","timestamp":1792173478552,"version":"4.4.0"},"reference-count":258,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["advanced.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advanced Therapeutics"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytokines are immunoregulatory proteins involved in many pathological states with promising potential as therapeutic agents. A diverse array of cytokines has been studied in preclinical disease models since the 1950s, some of which became successful biopharmaceutical products with the advancement of recombinant protein technology in the 1980s. However, following these early approvals, clinical translation of these natural immune signaling molecules has been limited due to their pleiotropic action in many cell types, and the fact that they have evolved to act primarily locally in tissues. These characteristics, combined with poor pharmacokinetics, have hindered the delivery of cytokines via systemic administration routes due to dose\u2010limiting toxicities. However, given their clinical potential and recent clinical successes in cancer immunotherapy, cytokines continue to be extensively pursued in preclinical and clinical studies, and a range of molecular and formulation engineering strategies are being applied to reduce treatment toxicity while maintaining or enhancing therapeutic efficacy. This review provides a brief background on the characteristics of cytokines and their history as clinical therapeutics, followed by a deeper discussion on the engineering strategies developed for cytokine therapies with a focus on the translational relevance of these approaches.<\/jats:p>","DOI":"10.1002\/adtp.202100035","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:31:30Z","timestamp":1617409890000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4035-0027","authenticated-orcid":false,"given":"Ivan S.","family":"Pires","sequence":"first","affiliation":[{"name":"Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology  500 Main Street Cambridge MA 02142 USA"},{"name":"Department of Chemical Engineering Massachusetts Institute of Technology  25 Ames Street Cambridge MA 02142 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula T.","family":"Hammond","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology  500 Main Street Cambridge MA 02142 USA"},{"name":"Department of Chemical Engineering Massachusetts Institute of Technology  25 Ames Street Cambridge MA 02142 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-1405","authenticated-orcid":false,"given":"Darrell J.","family":"Irvine","sequence":"additional","affiliation":[{"name":"Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology  500 Main Street Cambridge MA 02142 USA"},{"name":"Department of Biological Engineering Massachusetts Institute of Technology  Cambridge MA 02139 USA"},{"name":"Department of Materials Science and Engineering Massachusetts Institute of Technology  Cambridge MA 02139 USA"},{"name":"Ragon Institute of Massachusetts General Hospital Massachusetts Institute of Technology and Harvard University  Cambridge MA 02139 USA"},{"name":"Howard Hughes Medical Institute  Chevy Chase MD 20815 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"e_1_2_11_1_1","first-page":"150","volume-title":"Similarities of T Cell Function in Cell\u2010Mediated Immunity and Antibody Production","author":"Cohen S.","year":"1974"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-0323-1_12"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-455-1"},{"key":"e_1_2_11_4_1","volume-title":"Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook","author":"Wang C.","year":"2017"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901633"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2019.02.016"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0372-z"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0186-9"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0269-6"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-019-0106-3"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1994.5.2-153"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.10.1595"},{"key":"e_1_2_11_14_1","first-page":"10","author":"Dwyer C. J.","year":"2019","journal-title":"Front. Immunol."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12020183"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-32886-7_189"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-019-0156-z"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.03.041"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37346"},{"key":"e_1_2_11_20_1","volume-title":"Fundamental Immunology","author":"Paul W. E.","year":"2008"},{"key":"e_1_2_11_21_1","volume-title":"Autoimmunity: From Bench to Bedside [Internet]","author":"Mor\u00e1n G. A. G.","year":"2013"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1385\/JCD:1:2:187"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2014.05.014"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/AIA.0b013e318034194e"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0721-9"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0026"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-374001-4.00027-4"},{"key":"e_1_2_11_28_1","first-page":"695","volume":"47","author":"Cavaillon J. M.","year":"2001","journal-title":"Cell. Mol. Biol. (Noisy\u2010le\u2010grand)."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737772"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.9.4.532"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343"},{"key":"e_1_2_11_32_1","volume-title":"How the Immune System Works","author":"Sompayrac L.","year":"2019"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2729"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(92)80909-Z"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101469"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.08.002"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms151018574"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.2.4"},{"key":"e_1_2_11_39_1","doi-asserted-by":"crossref","unstructured":"J. M.Dayer TNF and its Inhibitor in Rheumatology Vol. 20 BioMed Central Ltd. 2018 p.\u00a0101.","DOI":"10.1186\/s13075-018-1607-y"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.44.6.753"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.02.011"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0008-8749(77)90262-3"},{"key":"e_1_2_11_43_1","volume":"2014","author":"Ningrum R. A.","year":"2014","journal-title":"Scientifica"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00204.x"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a032003"},{"key":"e_1_2_11_46_1","volume-title":"Directory of Approved Biopharmaceutical Products","author":"Spada S.","year":"2019"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01141-0"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-4-397"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2009.n.014"},{"key":"e_1_2_11_50_1","volume-title":"Oprelvekin","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/59.suppl_2.S6"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2006.00109.x"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2007-0229"},{"key":"e_1_2_11_54_1","unstructured":"Prometheus Laboratories FDA PROLEUKIN \u00ae (aldesleukin) Injection Label 2012."},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.2014.18"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2843"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0328-y"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0007-y"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-475X.2008.00410.x"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(87)90083-6"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-005-1319-7"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.6.1414.1414"},{"key":"e_1_2_11_63_1","first-page":"2541","volume":"90","author":"Leonard J. P.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1523-1"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-350-9_11"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005969024182"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.694"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.09.002"},{"key":"e_1_2_11_69_1","unstructured":"U.S. Food and Drug Administration Proleukin Toxicologist's Review (PLA# 97\u20130501) U.S. Food and Drug Administration Silver Spring MD1998."},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.135.4.2865"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.004"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4200"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700148"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01486739"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2005.10.006"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1238538"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.4103\/0975-1483.66810"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01112.x"},{"key":"e_1_2_11_80_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)00040-7","volume":"42","author":"Winkelhake J. L.","year":"1990","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.18.5662"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00206.x"},{"key":"e_1_2_11_83_1","first-page":"1661","volume-title":"Interferon Alfacon\u20101: A Review of its Pharmacology and Therapeutic Efficacy in the Treatment of Chronic Hepatitis C","author":"Melian E. B.","year":"2001"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.08.015"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2921"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14471-1"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1277306"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3246"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj070"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1109\/TVCG.2006.115"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/1.6.493"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815087116"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines7010006"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.3171\/2018.9.PEDS17225"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-456988"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2017.1284211"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.058"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0144-3"},{"key":"e_1_2_11_99_1","first-page":"203","volume":"17","author":"Pieczonka C. M.","year":"2015","journal-title":"Rev. Urol."},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00255"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01856-8"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.03.006"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.10.012"},{"key":"e_1_2_11_104_1","first-page":"583","volume-title":"Immunocytokines: A Novel Class of Potent Armed Antibodies","author":"Pasche N.","year":"2012"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1512"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3294"},{"key":"e_1_2_11_107_1","unstructured":"Roche Pipeline Summary https:\/\/www.roche.com\/dam\/jcr:e4ab3c09-5df7-4996-a93c-7cd0a28e3db4\/en\/irp200422-annex.pdf(accessed: May 2020)."},{"key":"e_1_2_11_108_1","unstructured":"Philogen PIPELINE \u2013 Philogen \u2013 Innovating Targeting http:\/\/www.philogen.com\/en\/products\/pipeline\/pipeline_16.html(accessed: May 2020)."},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1533.1533"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3109"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.tps9107"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.7090"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2490"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416159112"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzt045"},{"key":"e_1_2_11_116_1","first-page":"210","volume":"8","author":"Gillies S. D.","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz447.012"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-325266"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0433"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.12.081"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.875856"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902779186"},{"key":"e_1_2_11_123_1","volume":"9","author":"Huang Y. S.","year":"2014","journal-title":"PLoS One"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0152"},{"key":"e_1_2_11_125_1","first-page":"1","author":"Chuang Y. M.","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15373"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07882-8"},{"key":"e_1_2_11_128_1","year":"2020","journal-title":"Pharmaceutical R&D Pipeline"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-790402"},{"key":"e_1_2_11_130_1","unstructured":"Genentech Genentech: Our Pipeline https:\/\/www.gene.com\/medical-professionals\/pipeline(accessed: May 2020)."},{"key":"e_1_2_11_131_1","unstructured":"Generon Generon Corporation (Shanghai) Ltd http:\/\/www.generonbiomed.com\/en\/pipelinec.shtml(accessed: May 2020)."},{"key":"e_1_2_11_132_1","first-page":"2812","volume":"130","author":"Tahir S. K.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30148-7"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1738379"},{"key":"e_1_2_11_135_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000673"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000493"},{"key":"e_1_2_11_137_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0048-z"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215223"},{"key":"e_1_2_11_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30193-1"},{"key":"e_1_2_11_140_1","unstructured":"CHMP Withdrawal Assessment Report \u2013 Zafiride 2017."},{"key":"e_1_2_11_141_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000633"},{"key":"e_1_2_11_142_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau3259"},{"key":"e_1_2_11_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-020-0549-2"},{"key":"e_1_2_11_144_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2614"},{"key":"e_1_2_11_145_1","first-page":"215","volume-title":"Fusion Proteins for Half\u2010Life Extension of Biologics as a Strategy to Make Biobetters","author":"Strohl W. R.","year":"2015"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003699"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2205.bloodjournal8762205"},{"key":"e_1_2_11_148_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0129"},{"key":"e_1_2_11_149_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0622"},{"key":"e_1_2_11_150_1","first-page":"319","volume-title":"Protein PEGylation for Cancer Therapy: Bench to Bedside","author":"Gupta V.","year":"2019"},{"key":"e_1_2_11_151_1","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1339"},{"key":"e_1_2_11_152_1","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2017.1365878"},{"key":"e_1_2_11_153_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-019-0566-2"},{"key":"e_1_2_11_154_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425240802650568"},{"key":"e_1_2_11_155_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.200900218"},{"key":"e_1_2_11_156_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012073432301"},{"key":"e_1_2_11_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00028-5"},{"key":"e_1_2_11_158_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.2069"},{"key":"e_1_2_11_159_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0123"},{"key":"e_1_2_11_160_1","first-page":"404","volume-title":"Super\u2010Hydrophilic Zwitterionic Poly(Carboxybetaine) and Amphiphilic Non\u2010Ionic Poly(Ethylene Glycol) for Stealth Nanoparticles","author":"Cao Z.","year":"2012"},{"key":"e_1_2_11_161_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.144.1.209"},{"key":"e_1_2_11_162_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1993.8.199"},{"key":"e_1_2_11_163_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950815)76:4<687::AID-CNCR2820760424>3.0.CO;2-M"},{"key":"e_1_2_11_164_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00874158"},{"key":"e_1_2_11_165_1","doi-asserted-by":"publisher","DOI":"10.1086\/515653"},{"key":"e_1_2_11_166_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009818.pub2"},{"key":"e_1_2_11_167_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115110-00001"},{"key":"e_1_2_11_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.10.007"},{"key":"e_1_2_11_169_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.637"},{"key":"e_1_2_11_170_1","unstructured":"E.Lilly 2019 Eli Lilly and Company Financial Report 2020."},{"key":"e_1_2_11_171_1","unstructured":"K.Nyberg Pegilodecakin Fails to Improve Survival When Added to Second\u2010Line FOLFOX in PDAC 2020."},{"key":"e_1_2_11_172_1","volume-title":"Pegylated Interleukin\u201010: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics","author":"Autio K.","year":"2019"},{"key":"e_1_2_11_173_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179431"},{"key":"e_1_2_11_174_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1631"},{"key":"e_1_2_11_175_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1495"},{"key":"e_1_2_11_176_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1510"},{"key":"e_1_2_11_177_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1685489"},{"key":"e_1_2_11_178_1","unstructured":"J. L.Langowski P.Kirk M.Addepalli T.Chang V.Dixit G.Kim Y.Kirksey P.Kuo M.Lee M.Maiti W.Rubas P.Sims Y.Song Y.Tang L.Vanderveen P.Zhang S. K.Doberstein J.Zalevsky presented at 2017 ACR\/ARHP Annual Meeting San Diego CA November 2017."},{"key":"e_1_2_11_179_1","doi-asserted-by":"crossref","unstructured":"N. W.Nairn K.Grabstein K. D.Shanebeck G.Li A.Wang In Polymer\u2010Protein Conjugates Elsevier 2020 p.\u00a0317.","DOI":"10.1016\/B978-0-444-64081-9.00015-2"},{"key":"e_1_2_11_180_1","unstructured":"Synthorx Scientific Publications \u2013 Synthorx https:\/\/synthorx.com\/scientific-publications\/(accessed: June 2020)."},{"key":"e_1_2_11_181_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-0420-0"},{"key":"e_1_2_11_182_1","unstructured":"CHMP Committee for Medicinal Products for Human Use (CHMP) Assessment Report Plegridy International Non\u2010Proprietary Name: Peginterferon Beta\u20101a 2014."},{"key":"e_1_2_11_183_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym12020298"},{"key":"e_1_2_11_184_1","first-page":"10","volume-title":"PASylation\u00ae: A Versatile Technology to Extend Drug Delivery","author":"Binder U.","year":"2017"},{"key":"e_1_2_11_185_1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0022-3565(24)39226-2","volume":"293","author":"Chen S. A.","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_11_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00090-X"},{"key":"e_1_2_11_187_1","first-page":"669","volume-title":"Polymeric Protein Delivery Systems","author":"Lee K. Y.","year":"2007"},{"key":"e_1_2_11_188_1","first-page":"867","volume":"3","author":"Cole D. J.","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_11_189_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2006.26.593"},{"key":"e_1_2_11_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.02.031"},{"key":"e_1_2_11_191_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1672-x"},{"key":"e_1_2_11_192_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1259050"},{"key":"e_1_2_11_193_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmat2357"},{"key":"e_1_2_11_194_1","first-page":"1","volume-title":"Biomaterials for Enhancing Anti\u2010Cancer Immunity","author":"Koshy S. T.","year":"2016"},{"key":"e_1_2_11_195_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3104"},{"key":"e_1_2_11_196_1","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201902785"},{"key":"e_1_2_11_197_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2008.05.033"},{"key":"e_1_2_11_198_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2008.11.019"},{"key":"e_1_2_11_199_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.08.037"},{"key":"e_1_2_11_200_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3071"},{"key":"e_1_2_11_201_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8556"},{"key":"e_1_2_11_202_1","first-page":"37","volume":"47","author":"Morikawa K.","year":"1987","journal-title":"Cancer Res."},{"key":"e_1_2_11_203_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2017.08.003"},{"key":"e_1_2_11_204_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2016.01.029"},{"key":"e_1_2_11_205_1","first-page":"261","volume-title":"Biodegradable Microspheres for Protein Delivery","author":"Sinha V. R.","year":"2003"},{"key":"e_1_2_11_206_1","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2016.71"},{"key":"e_1_2_11_207_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199207000-00003"},{"key":"e_1_2_11_208_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7384789"},{"key":"e_1_2_11_209_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/978-3-642-81491-4_38","volume-title":"CancerChemo\u2010 and Immunopharmacology","author":"Fidler I. J.","year":"1980"},{"key":"e_1_2_11_210_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199407000-00005"},{"key":"e_1_2_11_211_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00346-6"},{"key":"e_1_2_11_212_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.26"},{"key":"e_1_2_11_213_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200008000-00006"},{"key":"e_1_2_11_214_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(01)00143-6"},{"key":"e_1_2_11_215_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2736(01)00377-7"},{"key":"e_1_2_11_216_1","doi-asserted-by":"publisher","DOI":"10.2165\/00137696-200402040-00002"},{"key":"e_1_2_11_217_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050455"},{"key":"e_1_2_11_218_1","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2004.03.022"},{"key":"e_1_2_11_219_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1752713"},{"key":"e_1_2_11_220_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01298.x"},{"key":"e_1_2_11_221_1","unstructured":"Biolex Locteron Controlled\u2010Release Interferon Alpha 2b 3 Studies at EASL 2010 Vienna \u20133 Company Press Releases 2010."},{"key":"e_1_2_11_222_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101136"},{"key":"e_1_2_11_223_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.08.095"},{"key":"e_1_2_11_224_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.36852"},{"key":"e_1_2_11_225_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6579"},{"key":"e_1_2_11_226_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.11.027"},{"key":"e_1_2_11_227_1","first-page":"212","volume-title":"Emerging Protein Delivery Methods","author":"Cleland J. L.","year":"2001"},{"key":"e_1_2_11_228_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2019.01.002"},{"key":"e_1_2_11_229_1","volume-title":"Preparing Aldesleukin For Pharmaceutical Use","author":"Maninder C\/O Chiron Corporation Hora","year":"2006"},{"key":"e_1_2_11_230_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-1236-7_8"},{"key":"e_1_2_11_231_1","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10143"},{"key":"e_1_2_11_232_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02088-w"},{"key":"e_1_2_11_233_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3343"},{"key":"e_1_2_11_234_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.0c03109"},{"key":"e_1_2_11_235_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-060418-052350"},{"key":"e_1_2_11_236_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2015.04.003"},{"key":"e_1_2_11_237_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.11.037"},{"key":"e_1_2_11_238_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2016.09.034"},{"key":"e_1_2_11_239_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4181"},{"key":"e_1_2_11_240_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmat3355"},{"key":"e_1_2_11_241_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2011.01.008"},{"key":"e_1_2_11_242_1","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10003"},{"key":"e_1_2_11_243_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040873"},{"key":"e_1_2_11_244_1","first-page":"49","volume-title":"The Translation of Cell\u2010Based Therapies: Clinical Landscape and Manufacturing Challenges","author":"Heathman T. R.","year":"2015"},{"key":"e_1_2_11_245_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1595582"},{"key":"e_1_2_11_246_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat9143"},{"key":"e_1_2_11_247_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0972"},{"key":"e_1_2_11_248_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0158-5"},{"key":"e_1_2_11_249_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357021778268"},{"key":"e_1_2_11_250_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy423"},{"key":"e_1_2_11_251_1","volume-title":"Liposome\u2010Anchored Local Delivery of Immunomodulatory Agents for Tumor Therapy","author":"Kwong B.","year":"2012"},{"key":"e_1_2_11_252_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030139"},{"key":"e_1_2_11_253_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24243"},{"key":"e_1_2_11_254_1","first-page":"1","volume-title":"Spotlight on Dinutuximab in the Treatment of High\u2010Risk Neuroblastoma: Development and Place in Therapy","author":"Keyel M. E.","year":"2019"},{"key":"e_1_2_11_255_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21596"},{"key":"e_1_2_11_256_1","first-page":"12","volume-title":"What, Why, Where, and When: Bringing Timing to Immuno\u2010Oncology","author":"Rothschilds A. M.","year":"2019"},{"key":"e_1_2_11_257_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1558678"},{"key":"e_1_2_11_258_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0577"}],"container-title":["Advanced Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/adtp.202100035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/adtp.202100035","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/adtp.202100035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:40:01Z","timestamp":1759776001000},"score":1,"resource":{"primary":{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/10.1002\/adtp.202100035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":258,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/adtp.202100035"],"URL":"https:\/\/doi.org\/10.1002\/adtp.202100035","archive":["Portico"],"relation":{},"ISSN":["2366-3987","2366-3987"],"issn-type":[{"value":"2366-3987","type":"print"},{"value":"2366-3987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"2021-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2100035"}}